PMID- 34686712
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20230921
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 11
IP  - 1
DP  - 2021 Oct 22
TI  - Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 
      rearrangement.
PG  - 20939
LID - 10.1038/s41598-021-00309-3 [doi]
LID - 20939
AB  - In patients with advanced non-small cell lung cancer (NSCLC), comprehensive 
      genetic diagnostics is currently carried out in order to qualify for molecularly 
      targeted therapies and immunotherapy. The aim of the study was to assess the 
      usefulness of the reverse transcriptase (RT-PCR) method in the diagnosis of gene 
      rearrangements, the effectiveness of EGFR, ALK, ROS1, and PD-L1 inhibitors in 
      first-line treatment in NSCLC patients. We enrolled 95 non-squamous NSCLC 
      patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 
      protein expression. We used the real time PCR, fluorescence in situ hybridization 
      (FISH), immunohistochemistry (IHC) and RT-PCR techniques for determination of 
      predictive factors. In patients with ALK and ROS1 genes alteration, the median 
      overall survival was 34 months in crizotinib treated patients and 6 months in 
      patients who received chemotherapy (HR = 0.266, p = 0.0056). The risk of death 
      was lower in patients treated with molecularly targeted therapies or 
      immunotherapy compared to patients with predictive factors without personalized 
      treatment (HR = 0.265, 95% CI 0.116-0.606) and to patient without predictive 
      factors who received chemotherapy (HR = 0.42, 95% CI 0.162-1.09). Diagnosis of 
      predictive factors and implementation of personalized treatment are key to 
      prolonging the survival in advanced NSCLC patients.
CI  - (c) 2021. The Author(s).
FAU - Krawczyk, Pawel
AU  - Krawczyk P
AUID- ORCID: 0000-0001-8400-4452
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Grenda, Anna
AU  - Grenda A
AUID- ORCID: 0000-0002-2112-8092
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Terlecka, Paulina
AU  - Terlecka P
AUID- ORCID: 0000-0001-8806-8197
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland. paulina.chwil@gmail.com.
AD  - Department of Endocrinology, Diabetology and Metabolic Diseases, Medical 
      University of Lublin, Lublin, Poland. paulina.chwil@gmail.com.
FAU - Blach, Justyna
AU  - Blach J
AUID- ORCID: 0000-0003-4154-156X
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
AD  - Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland.
FAU - Wojas-Krawczyk, Kamila
AU  - Wojas-Krawczyk K
AUID- ORCID: 0000-0001-9947-5169
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Kucharczyk, Tomasz
AU  - Kucharczyk T
AUID- ORCID: 0000-0002-2678-8655
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Chmielewska, Izabela
AU  - Chmielewska I
AUID- ORCID: 0000-0002-0948-9071
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Kieszko, Robert
AU  - Kieszko R
AUID- ORCID: 0000-0001-5775-0193
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Jarosz, Bozena
AU  - Jarosz B
AUID- ORCID: 0000-0003-0956-7727
AD  - Neuropathology Laboratory, Department of Neurosurgery and Pediatric Neurosurgery, 
      Medical University of Lublin, Lublin, Poland.
FAU - Gil, Michal
AU  - Gil M
AUID- ORCID: 0000-0002-9965-261X
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Reszka, Katarzyna
AU  - Reszka K
AUID- ORCID: 0000-0001-5612-1598
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
FAU - Milanowski, Janusz
AU  - Milanowski J
AUID- ORCID: 0000-0002-8616-596X
AD  - Department of Pneumonology, Oncology and Allergology, Medical University of 
      Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
LA  - eng
PT  - Journal Article
DEP - 20211022
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Aged
MH  - Anaplastic Lymphoma Kinase/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*metabolism
MH  - Crizotinib/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Immunotherapy/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lung Neoplasms/*drug therapy/*metabolism
MH  - Male
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/*metabolism
MH  - Proto-Oncogene Proteins/*metabolism
PMC - PMC8536721
COIS- The authors declare no competing interests.
EDAT- 2021/10/24 06:00
MHDA- 2022/01/22 06:00
PMCR- 2021/10/22
CRDT- 2021/10/23 05:55
PHST- 2021/05/30 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/10/23 05:55 [entrez]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
PHST- 2021/10/22 00:00 [pmc-release]
AID - 10.1038/s41598-021-00309-3 [pii]
AID - 309 [pii]
AID - 10.1038/s41598-021-00309-3 [doi]
PST - epublish
SO  - Sci Rep. 2021 Oct 22;11(1):20939. doi: 10.1038/s41598-021-00309-3.